Why Merck Is Buying Themis
By Dan Anderson ● May 27, 2020
Merck & Co., Inc. (NYSE: MRK) and Themis -- which is a company focused on vaccines and immune-modulation therapies for infectious diseases and cancer -- announced that the companies have entered into a definitive agreement under which Merck will buy Themis.